CMPS
COMPASS Pathways plc·Healthcare
5.53
0.896%(−0.05)
Market ClosedLast Updated: — ET
52W L: $2.2552W H: $8.90
CMPS NEWS
businesswire.com
3d ago
Compass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Needham Virtual Healthcare Conference on April 14, 2026 and will participate in a fireside chat at 12:45 pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will.
businesswire.com
3d ago
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seven newly hired non-executive employees. The equity awards were granted on April 1, 2026 and consisted of options to purchase an aggregate of 117,445 shares and restricted share units or, in the case of emp.
defenseworld.net
Apr 3
Compass Pathways (NASDAQ:CMPS) & Elevance Health (NYSE:ELV) Financial Comparison
Elevance Health (NYSE: ELV - Get Free Report) and Compass Pathways (NASDAQ: CMPS - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability. Valuation and Earnings This table compares Elevance Health
businesswire.com
Mar 24
Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported the fourth quarter and full-year 2025 financial results and business highlights. “COMP360 is shaping the future of mental healthcare, and we are moving the field of psychiatric medicine forward for the millions of people urgently needing better options. As the potential first classic psychedelic ap.
defenseworld.net
Mar 21
Compass Pathways Eyes Rolling FDA Filing for COMP360, Preps TRD Launch Ahead of Q3 Data
Compass Pathways (NASDAQ: CMPS) executives outlined plans for a potential U.S. regulatory filing and commercial launch preparation for its investigational psilocybin therapy, COMP360, during a recent fireside chat. Chief Executive Officer Kabir Nath and Chief Commercial Officer Lori Englebert discussed upcoming clinical milestones, the company's approach to a rolling regulatory submission, and key operational issues they
businesswire.com
Mar 12
Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Stifel 2026 Virtual CNS Forum, from March 17-18, 2026, and will participate in a fireside chat on March 18, 2026, at 10:30am ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of.
